A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).

NCT07641426 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Antibody Mediated Rejection

Interventions

DRUG: CID-103

Sponsor

CASI pharmaceuticals, Inc.

Collaborators

[object Object]